Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Bayer, MD Anderson partner to evaluate how a drug may affect patient's disease-related symptoms

Bayer, MD Anderson partner to evaluate how a drug may affect patient's disease-related symptoms

When cancer patients take part in a clinical trial to develop new therapies, they and their physicians want to know how they will feel and function during treatment. A new collaboration between Bayer and The University of Texas MD Anderson Cancer Center will go straight to the patients to learn how certain investigational new drugs affect them. [More]
Study examines effects of beetroot juice on physical function of COPD patients

Study examines effects of beetroot juice on physical function of COPD patients

A Wake Forest University study to investigate the effects of acute beetroot juice ingestion on the exercise capacity of COPD patients shows some promise, but a larger clinical trial is needed to verify results. [More]
Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease. [More]
Study finds relationship between menopausal symptoms, bone health in postmenopausal women

Study finds relationship between menopausal symptoms, bone health in postmenopausal women

The first large prospective cohort study to examine the relationship between menopausal symptoms and bone health in postmenopausal women has found that those who experience moderate to severe hot flashes and night sweats during menopause tend to have lower bone mineral density and higher rates of hip fracture than peers with no menopausal symptoms. [More]
Voices of loved ones telling familiar stories can help awaken unconscious brain, speed coma recovery

Voices of loved ones telling familiar stories can help awaken unconscious brain, speed coma recovery

"Can he hear me?" family members are desperate to know when a loved one with a traumatic brain injury is in a coma. [More]

Nevro gets FDA approval letter for Senza spinal cord stimulation system

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it has received a letter from the U.S. Food and Drug Administration informing the company of the approvability of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. [More]
Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

Alexza Pharmaceuticals, Inc. announced today that it has initiated a Phase 2a study of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). [More]
NCCS launches human clinical trial of new cancer vaccine

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years. [More]
Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison. [More]
U.S. News & World Report recognizes Jenny Craig with Best Diets rankings

U.S. News & World Report recognizes Jenny Craig with Best Diets rankings

U.S. News & World Report, a nationally recognized publisher of consumer advice and rankings, recognized Jenny Craig as the 2nd Best Commercial Diet Plan, 2nd Easiest Diet to Follow, and 3rd Best Weight-Loss Diet in its annual Best Diets rankings. [More]
Penn, Spark Therapeutics expand strategic relationship to develop treatment for progressive blindness

Penn, Spark Therapeutics expand strategic relationship to develop treatment for progressive blindness

The University of Pennsylvania has announced an expanded relationship with Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating, genetic diseases. [More]
Pfizer, Avon Foundation for Women reveal Avon-Pfizer Metastatic Breast Cancer Grants Program recipients

Pfizer, Avon Foundation for Women reveal Avon-Pfizer Metastatic Breast Cancer Grants Program recipients

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify. [More]
Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Researchers have tracked the genetic mutations that have occurred in the Ebola virus during the last four decades. Their findings, published in mBio, the online open-access journal of the American Society for Microbiology, identified changes in the current West African outbreak strain that could potentially interfere with experimental, sequence-based therapeutics. [More]
FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. [More]
Caris Life Sciences launches Caris Centers of Excellence for Precision Medicine Network

Caris Life Sciences launches Caris Centers of Excellence for Precision Medicine Network

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced the establishment of the Caris Centers of Excellence for Precision Medicine Network, and appointed John L. Marshall, M.D., as Chairman of the Network. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
AMRI awarded NIH contract for drug development services

AMRI awarded NIH contract for drug development services

AMRI today announced it received a 10-year federal contract award from the National Institutes of Health for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network (BPN). [More]
Prevalence of falls among older adults on the rise

Prevalence of falls among older adults on the rise

Over a 12-year period, the prevalence of self-reported falls among older adults appeared to be on the rise, according to a new nationally representative study. [More]
Unmet medication need in neuropathic pain

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients. [More]
GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]